A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review

A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review

Cardiovascular and renal complications remain leading causes of morbidity and mortality among individuals with type 2 diabetes mellitus (T2DM). Since 2015, large-scale cardiovascular outcome trials (CVOTs) have demonstrated that sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like pe...

Full description

Saved in:
Bibliographic Details
Main Authors: David Aristizábal-Colorado, David Corredor-Rengifo, Santiago Sierra-Castillo, Carolina López-Corredor, David-Alexander Vernaza-Trujillo, Danilo Weir-Restrepo, Juan S. Izquierdo-Condoy, Esteban Ortiz-Prado, Jorge Rico-Fontalvo, Juan-Esteban Gómez-Mesa, Alin Abreu-Lomba, Wilfredo-Antonio Rivera-Martínez
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Endocrinology
Subjects:
cardiovascular outcomes
SGLT2 inhibitors
GLP-1 agonists
combination therapy
heart failure
renal outcomes
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2025.1605746/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2025.1605746/full

Similar Items